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Background. The burden of cardiovascular disease is expected to escalate in developing countries. However, studies and guidelines 
concerning atrial fibrillation (AF) are restricted to the developed world.
Objectives. To assess the treatment modalities of AF in South Africa.
Methods. A cross-sectional, observational, multicentre, national registry of the treatment of 302 patients with AF was conducted from 
February 2010 to March 2011. Specific drug use for rate or rhythm control, as well as drug use for stroke prevention, was surveyed. Events 
during the 12 months prior to the survey were also characterised, including non-drug treatments, resource utilisation and complications.
Results. The single most prevalent clinical characteristic was hypertension (65.9%). Rhythm control was being pursued in 109 patients 
(36.1%) with class Ic and class III antiarrhythmic agents, while rate control, mainly with beta-blockers, was pursued in the remainder of the 
patients. Concomitant use of other cardiovascular drugs was high, and 75.2% of patients were on warfarin for stroke prevention. There was 
a high burden of AF-related morbidity during the preceding year, with 32.5% reporting a history of heart failure, 8.3% a stroke and 5.3% 
a transient ischaemic attack. Therapeutic success, as defined by either the presence of sinus rhythm or rate-controlled AF, was achieved in 
86.8% as judged clinically by the treating physician, but in only 70.2% according to the electrocardiogram criterion of heart rate ≤80 bpm.
Conclusion. There were no striking differences from previously reported registries worldwide. The lack of application of strict rate control 
criteria is highlighted.
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Atrial fibrillation (AF) is the most common cardiac 
arrhythmia, with a prevalence of 5 - 6% in the 
65-year-old population, increasing up to 10% in the 
>80 years population.[1-4]
Despite the improvement in primary and secondary 
prevention of predisposing underlying cardiac conditions such as 
ischaemic heart disease and hypertension, the prevalence of AF 
continues to rise in developed countries due to ageing and increasing 
obesity of the population.[3,5,6] The treatment of AF is undergoing 
significant revision throughout the world and in a number of ways, 
especially with regard to stroke prevention, ablation for rhythm 
control, and novel antiarrhythmic drugs. This has triggered a number 
of guidelines[7,8] and guideline updates,[9,10] as well as a number of 
registries and surveys on AF and AF management in various parts 
of the world (e.g. Nieuwlaat et al.[11] and Camm et al.[12]). In South 
Africa (SA), the prevalence of AF in the urban black population has 
recently been documented to be 7% in a cardiovascular disease cohort 
(8% of heart failure patients, 4% of hypertensive patients, and 13% of 
valvular disease patients).[13] However, very little has been published 
on AF management outside the deve loped world. This prompted the 
Assessment of the Therapeutic Management of Patients with Atrial 
Fibrillation in South Africa (SAFIR-RSA). The principal objective of 
the study was to assess the baseline characteristics of patients with AF 
and the treatment modalities utilised, particularly the use of rate and 
rhythm control strategies. The study also looked at hospitalisation rates 
and prevention of thromboembolism.
Methods
SAFIR-RSA was a prospective cross-sectional, non-interventional, 
observational disease registry carried out in 29 medical institutions 
spanning nine urban centres in SA. Patients were largely drawn from 
the private insured medical sector and therefore represent a relatively 
affluent stratum of the population.
Patients
The study protocol was approved by an independent ethics 
committee, and written informed consent was obtained from patients 
before study entry in accordance with Helsinki (1964) ethical 
recommendations. Adult patients (≥21 years) with electrographically 
documented AF were enrolled in the registry.  Patients were excluded 
if they had developed AF within 3 months of cardiac surgery, had 
acute AF apparently precipitated by non-cardiac conditions (e.g. 
pneumonia), or had recently participated in an AF trial.
Procedure
A medical history taken at enrolment included recording each 
patient’s treatment, the clinical presentation of AF, the presence or 
absence of comorbidities, and all data pertaining to the primary and 
secondary outcomes (see below). The physicians or cardiologists in 
each participating medical centre completed a standardised 6-page 
case report form for every enrolled patient.
Primary evaluation criteria
These included: (i) the prevalence of AF treatment modalities, 
namely the proportion of patients receiving rhythm control agents 
(class I and III) and/or rate control agents (class II and IV, and 
cardiac glycosides), cardioversion, ablation or other procedures; and 
(ii) the use of treatments to prevent thromboembolism, namely the 
proportion of patients taking vitamin K antagonists, acetylsalicylic 
acid or other antiplatelet agents. Any other cardiovascular treatments 
were also noted.
Secondary evaluation criteria
These included: (i) the proportion of patients with controlled AF, 
defined as either in sinus rhythm (SR) (recorded during the visit) or 
at heart rate control target (≤80 bpm at rest); and (ii) the incidence 
of clinical outcomes in the year preceding the inclusion, defined as 
hospitalisations for AF and other related cardiovascular events such 
as stroke, transient ischaemic attack, heart failure and myocardial 
ischaemia.
Statistical analysis
The data from all the participating medical centres were combined 
and treated as one dataset for the purposes of the analysis. Data 
analysis was performed with SAS statistical software, Release 9.2 (SAS 
Institute, USA). Continuous variables are reported as mean (standard 
deviation (SD)) and non-continuous variables as number/percentage 
of patients. The statistical analysis was mainly of a descriptive nature, 
and sub-analyses were not prespecified in the protocol. Post-hoc sub-
analyses were performed using Fisher’s exact test. A p-value of <0.05 
was considered statistically significant.
Results
The study population consisted of 302 AF patients (59.9% male) 
from 29 centres, enrolled from 18 February 2010 to 9 March 2011. 
The mean age was 67 (SD 13) years (range 21 - 95). The mean waist 
circumference was 101.6 (SD 17.8) cm and the mean body mass index 
(kg/m2) 28.8 (SD 5.9), indicating a high prevalence of overweight 
patients in the cohort.
Clinical characteristics
The single most prevalent clinical characteristic was hypertension 
(65.9%). Other coronary risk factors were also frequent (dyslipidaemia 
48.3% and diabetes 15.6%). Concomitant structural heart disease was 
common, with 27.5% having valvular disease (of whom 79.5% had 
mitral valve disease), 26.8% coronary artery disease, and 32.5% heart 
failure; 28.5% of these patients had New York Heart Association class 
III or IV symptoms. In keeping with these comorbidities, 27.5% of 
patients had a history of previous cardiac or vascular interventions. 
Non-cardiac comorbidities were not common, comprising thyroid 
disease in 14.2% (3.3% hyperthyroid and 10.9% hypothyroid) and 
renal disease in 10.9% (Table 1).
The time course of AF was paroxysmal in 32.1% of patients, 
persistent in 21.2% and permanent in 46.7%. During the preceding 12 
months, 40.7% of patients had experienced symptoms of AF.
Pharmacological treatment
The drug therapy at the time of the survey visit is listed in Table 2. For 
the purposes of this analysis, ‘rhythm control’ was defined as the chronic 
use of class Ic or class III drugs for the maintenance of SR, and all others 
were deemed ‘rate control’. Rhythm control was being pursued in 109 
patients (36.1%) with class Ic and class III agents, while rate control was 
pursued in the remainder (63.9%). Amiodarone accounted for 79.4% 
of class III drugs used. A number of patients in the rhythm control 
group were receiving rate control medications in addition, but this 
number is not extractable from the data. Beta-blockers were the most 
frequently used rate control drugs. Combinations of beta-blockers, 
digoxin and rate-controlling calcium channel blockers were often 
employed. Concomitant use of other cardiovascular drugs was high, 
especially diuretics (53.0%), statins (44.0%), angiotensin-converting 
enzyme inhibitors (39.1%) and angiotensin receptor blockers (22.5%). 
For stroke prevention, 75.2% were on warfarin, 39.4% on aspirin and 
5.0% on clopidogrel.
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Events and hospitalisations in the 
preceding 12 months
Treatments for AF in the preceding 12 months 
included pharmacological cardioversion 
(17.5%), electrical cardioversion (13.2%), 
catheter ablation (4.2%) and pacemaker 
implantation (5.3%). Interestingly, a number 
of patients had an unusually large number of 
cardioversions in the previous year: 6 patients 
had two attempts at electrical cardioversion, 
2 underwent three attempts, and a further 2 
underwent four attempts. One patient had 
six pharmacological cardioversion attempts.
Of the total cohort, 104 patients (34.4%) 
had required hospitalisation during the 
previous 12 months, with a third of these 
patients requiring multiple hospitalisations. 
AF-related morbidity requiring hospitali-
sation was particularly frequent for heart 
failure (11.6% of study patients, 35/98 with 
heart failure), and for stroke, transient 
ischaemic attack and peripheral embolism 
(3.9% of study patients, 12/58 with these 
conditions) (Table 3). Haemorrhage occ urred 
in 23 patients (7.6%) during the preceding 
year, but was considered to be serious enough 
to warrant hospitalisation in only 8 cases. 
One patient had intracranial haemorrhage. 
The mean duration of hospital stay was 5.2 
days. The average number of outpatient 
consultations for AF or other cardiovascular 
reasons in the preceding year was 1.74.
Control of AF
The rhythm status of patients at the time 
of the survey is shown in Table 4. Only 85 
patients (28.1% of the total study cohort) were 
in SR; notably, 31 of these were on rate control 
medications alone. Of the patients in AF at 
the time of the survey, 81.5% were judged in 
the opinion of the enrolling investigator to be 
satisfactorily rate controlled. However, when 
utilising a strict electrocardiogram (ECG) 
criterion of rate ≤80 bpm, only 58.4% of 
patients in AF would fulfil this definition. 
Using the ‘lenient’ rate control criterion of 
≤110 bpm proposed by the RACE II trial,[8] 
90.6% of patients would fulfil this definition. 
‘Therapeutic success’ as defined by either 
the presence of SR or rate-controlled AF was 
achieved in 86.8% of the total population on 
the basis of the clinicians’ clinical judgement, 
but only in 70.2% as judged by the EGC 
criterion of rate ≤80 bpm.
A post-hoc sub-analysis was performed 
to compare the strategies of rhythm 
control with rate control (Table 5). Patients 
prescribed rhythm control medications were 
somewhat younger, had more medication 
changes in the preceding year, had more 
hospitalisations for AF or cardiovascular 
reasons, and underwent pharmacological 
and electrical cardioversion more frequently 
than the rate control group. The rhythm 
control group had significantly more 
hospitalisations for coronary artery disease 
(50.0% v. 16.3%), myocardial infarction (28.6 
v. 0%) and heart failure (57.6% v. 25.8%).
Prevention of thromboembolic 
complications
The mean CHA2DS2-VASc score (congestive 
heart failure or left ventricular dysfunction, 
hypertension, age ≥75 (2 points), diabetes, 
stroke (2 points), vascular disease, age 
65  - 74, sex category) for the entire cohort 
of patients was 3.08, and there was no 
significant difference in scores of patients 
on warfarin v. those not on warfarin (3.12 
v. 2.96, respectively). Of patients not using 
vitamin K antagonists, 78.6% had CHA2DS2-
VASc scores ≥2.
There was a poor correlation between 
the actual CHA2DS2-VASc score and use 
of anticoagulation, as follows: score of 0 
(65%); score of 1 (83%); score of 2  (68%); 
score of 3 (76%); score of 4 (79%); score of 
5 (76%); score of 6 (81%); score of 7 (25%, 
1/4 patients); score of 8 (100%, 4/4 patients).
Discussion
The primary outcome measure in the SAFIR-
RSA survey was to evaluate the incidence of 
AF treatment modalities and thromboembolic 
prevention treatments in a cross-sectional 
Table 1. Clinical characteristics
History of 
condition
n (%)
Treated for condition in 
preceding 12 months
n (% of those with condition)
Cardiac risk factors (N=302)
Smoking
Current 27 (9.0)
Former 123 (40.7)
Never 142 (47.0)
Hypertension 199 (65.9) 198 (99.5)
Diabetes* 47 (15.6) 44 (93.6)
Dyslipidaemia 146 (48.3) 127 (87.0)
Cardiac comorbidities (N=302)
Coronary artery disease 81 (26.8) 23 (28.4)
Myocardial infarction 34 (11.3) 4 (11.8)
Peripheral arterial disease 9 (3.0) 1 (11.1)
Carotid stenosis 3 (1.0)
Valvular heart disease 83 (27.5) 9 (10.8)
Arrhythmia other than AF† 42 (13.9) 11 (26.2)
Total 83 (27.5) 20 (24.1)
Cardiac and vascular interventions (N=83)
PCI 23 (27.7)
CABG 16 (19.3)
Carotid intervention 1 (1.2)
Valvular surgery 25 (30.1)
CABG + valvular surgery 3 (3.6)
PCI + CABG 4 (4.8)
PCI + valvular surgery 1 (1.2)
PCI + carotid intervention 1 (1.2)
Unknown 9 (10.9)
Non-cardiac comorbidities (N=302)
Thyroid disease 43 (14.2)
Renal disease 33 (10.9)
AF = atrial fibrillation; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft.
*97.9% had type 2 diabetes.
†60.4% had atrial flutter. 
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representative cohort of patients with AF in SA. The results clearly showed 
that the majority of patients were receiving rate control therapy (63.9%), 
usually in the form of beta-blockers, either alone or in combination with 
other rate control agents. Rhythm control therapy for the remainder of 
the patients consisted primarily of class III agents. Concomitant use of 
other cardiovascular drugs was high in both treatment strategies. Since 
the patient cohort included the elderly, with a high frequency of other 
cardiac risk factors and structural heart disease, it is not surprising that 
the majority were being treated with a rate control strategy. According to 
European Society of Cardiology guidelines, rate control is a reasonable 
strategy in elderly patients in whom the level of symptoms related to 
AF is deemed acceptable.[8] Nevertheless, the findings do suggest that 
clinicians in SA apply lenient rate control criteria and judge patients to be 
rate controlled with a resting pulse rate of less than 110 bpm.
There were no striking differences in the baseline clinical character-
istics of this study population when compared with other worldwide 
registries. Notably, the prevalence of underlying comorbidities such as 
coronary artery disease, valvular disease and heart failure in the present 
study is similar (~20 - 30% for each) to those reported in the developed 
world.[8] This is perhaps not surprising because, although the aim of this 
study was to focus for the first time on SA patients, the cohort was largely 
derived (88.7%) from insured patients, a more affluent sector of the 
population that would more closely approximate a First-World setting. 
The racial groups of the sub jects, frequently used as a proxy for socio-
economic status, are unknown. 
The primary outcome measure of the SAFIR-RSA survey also 
included an assess ment of the use of thromboembolic prevention 
treatments. The novel oral anti coagulants were not yet in use at 
the time of the survey. The findings show that the large majority 
of patients (75.2%) were receiving warfarin for stroke prevention. 
There were, however, a significant number of patients not receiving 
anticoagulation who, with CHA2DS2-VASc scores ≥2, should have 
had thromboembolic prevention therapy according to current 
treatment guidelines.[10] Nearly all the patients on warfarin had had 
international normalised ratio monitoring during the previous 6 
months. This diligent monitoring may account for the low rate of 
hospitalisation for haemorrhage of only 2.6% (8 patients) during the 
preceding year, compared with rates of 6.8 - 7.2% reported in other 
observational studies on older patients with AF receiving warfarin.[14]
In the present survey, hospitalisations for coronary artery disease, 
myocardial infarction and heart failure occurred more frequently in 
the group on antiarrhythmic agents. It is not clear whether these 
developments are a result of antiarrhythmic drug therapy, or whether 
rhythm control is preferred as a strategy in patients with these conditions.
Study limitations
There are a number of limitations to this study. The patient sample 
does not necessarily reflect the true cross-sectional population of 
AF patients in SA, as most had medical insurance coverage. Site 
selection bias is likely, with over-representation of cardiologists with 
specialisation or particular interest in AF. Case selection bias may also 
have been introduced because it was not mandated that consecutive 
cases be included at each site. Investigator knowledge of the sponsor 
Table 2. Medication at time of visit, N=302 patients
Medication n (%)
Cardiovascular 109* (36.1) 
Rhythm control agents
Ic 9 (3.0)
III 102 (33.8)
Rate control agents
Beta-blockers (excluding sotalol) 180 (59.6)
HR-lowering CCBs 40 (13.2)
Cardiac glycosides 76 (25.2)
Other
Beta-blockers (not prescribed for AF) 44 (14.6)
Diuretics 160 (53.0)
Dihydropyridine CCBs 43 (14.2)
ACE inhibitors 118 (39.1)
Angiotensin II receptor antagonist 68 (22.5)
Vasodilators 10 (3.3)
Other antihypertensives 19 (6.3)
Statins 133 (44.0)
Other lipid-lowering agents 7 (2.3)
Oral antidiabetic agents 45 (14.9)
Insulin 13 (4.3)
Antithrombotic 
Vitamin K antagonist 227 (75.2)
Acetylsalicylic acid 119 (39.4)
Clopidogrel 15 (5.0)
Other antiplatelet/anticoagulant agents 5 (1.7)
INR in past 6 months 218 (96.0)†
HR = heart rate; CCBs = calcium channel blockers; AF = atrial fibrillation;  
ACE = angiotensin-converting enzyme; INR = international normalised ratio.
*Two patients were on both class Ic and class III agents.
†75 missing values.
Table 3. AF morbidity in preceding 12 months
Diagnosis
History of 
condition
n/N (% )
Hospitalised in 
preceding 12 
months
n (% of those with 
condition)
Heart failure (N=302) 98 (32.5) 35 (35.7)
NYHA class
 I 22/98 (22.5)
 II 48/98 (49.0)
 III 26/98 (26.5)
 IV 2/98 (2.0)
LVEF (%) in preceding 
12 months (N=302) 
243 (80.4)
 <30 7/243 (2.9)
 30 - 40 26/243 (10.7)
 41 - 50 33/243 (13.6)
 >50 177/243 (72.8)
Stroke (N=302) 36 (11.9) 3 (8.3)
TIA (N=302) 16 (5.3) 7 (43.8)
Peripheral embolic 
events (N=302)
6 (2.0) 2 (33.3)
AF = atrial fibrillation; NYHA = New York Heart Association; LVEF = left ventricular 
ejection fraction; TIA = transient ischaemic attack.
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may have introduced an additional bias in 
favour of patients on amiodarone.
Conclusions
The data in the SAFIR-RSA survey conform 
to similar registries in the developed world. 
Despite the focus on a relatively affluent 
sub-sector of the SA population, resulting 
in a near duplication of studies carried out 
in other developed countries, this is the first 
epidemiological study generating data on 
management of AF in SA. AF is a significant 
burden in cardiology practice in this country, 
with considerable resource utilisation and 
morbidity for patients. This survey highlights 
a lack of rigour in applying definitions 
of rate control and under-utilisation of 
antithrombotic therapy. Although only 
a ‘snapshot’, clinicians should be aware of 
these findings and attempt to improve drug 
utilisation and patient outcomes.
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Table 4. Current control at time of the survey
n (%) Total patients, N
In SR at visit 85 (28.1) 302
In AF at visit 217 (71.9)
 Symptomatic 68 (22.5)
In AF but rate controlled
 Investigator opinion 177 (81.5) 217
 ECG criterion, HR ≤80 bpm 125 (58.4) 214*
 ECG criterion, HR ≤110 bpm 194 (90.6)  214*
Therapeutic success (in SR or in AF with rate 
controlled) 
 Investigator opinion 262 (86.8) 302
 ECG criteria 210 (70.2) 299*
SR = sinus rhythm; AF = atrial fibrillation; ECG = electrocardiogram; HR = heart rate.
*3 patients in AF did not have ECGs.
Table 5. Sub-analysis of rate control v. rhythm control strategies 
Rate control
(N=193)
Rhythm control
(N=109) p-value*
Age (years) 68.3 65.3 0.05
Pharmacological cardioversion, n (%) 6 (3.2) 47 (43.9) <0.001
Electrical cardioversion, n (%) 16 (8.4) 24 (22.2) 0.001
AF at visit, n (%) 162 (83.9) 55 (50.5) <0.001
Rate control, n (%) 141 (88.1) 36 (65.4) <0.001
Hospitalisation for AF or CV reasons, 
n (%)†
49 (25.4) 55 (50.5) <0.001
History of CVD, n (%) 51 (27.0) 30 (27.8) 0.892
Hospitalisation for CVD, n/N (%)† 8/49 (16.3) 15/30 (50.0) 0.002
History of MI, n (%) 20 (10.5) 14 (13.0) 0.57
Hospitalisation for MI, n/N (%)† 0 (0) 4/14 (28.6) 0.022
History of CHF, n (%) 64 (33.3) 34 (31.2) 0.789
Hospitalisation for CHF, n (%)† 16/62 (25.8) 19/33 (57.6) 0.004
AF = atrial fibrillation; CV = cardiovascular; CVD = cardiovascular disease; MI = myocardial infarction; CHF = chronic 
heart failure.
*Fisher’s exact test except for age, where Student’s t-test was used. Significance values should be interpreted with caution, as 
the study was not designed for this comparison.
†Preceding 12 months.
